Handok-Aventis Pharma launches anti-rheumatic drug "Arava"

Published: 2003-04-09 06:56:00

Updated: 2003-04-09 06:56:00

Handok-Aventis Pharma has newly launched Arava (leflunomide), a new disease-modifying anti-rheumatic drug (DMARD) that reduces inflammation and slows disease progression of rheumatoid arthritis (RA).

Arava is indicated in adults for the treatment of active rheumatoid arthritis to retard struc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK